BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33931487)

  • 21. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
    Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A
    Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
    Wang Z; Yin M; Chu P; Lou M
    Aging (Albany NY); 2019 Sep; 11(17):7187-7196. PubMed ID: 31484165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels.
    Sato K; Hikita H; Myojin Y; Fukumoto K; Murai K; Sakane S; Tamura T; Yamai T; Nozaki Y; Yoshioka T; Kodama T; Shigekawa M; Sakamori R; Tatsumi T; Takehara T
    PLoS One; 2020; 15(7):e0235573. PubMed ID: 32609742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukemia inhibitory factor regulates trophoblast giant cell differentiation via Janus kinase 1-signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway.
    Takahashi Y; Takahashi M; Carpino N; Jou ST; Chao JR; Tanaka S; Shigeyoshi Y; Parganas E; Ihle JN
    Mol Endocrinol; 2008 Jul; 22(7):1673-81. PubMed ID: 18451094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Free LIF receptor α-chain distal cytoplasmic motifs enhance Jak2-independent STAT3 phosphorylation and induce differentiation in HL-60 cells.
    Sun Q; Wang J; Xiong J; Yang L; Liu H
    Oncol Rep; 2011 Aug; 26(2):399-404. PubMed ID: 21567092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
    Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
    Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.
    Vicent S; Chen R; Sayles LC; Lin C; Walker RG; Gillespie AK; Subramanian A; Hinkle G; Yang X; Saif S; Root DE; Huff V; Hahn WC; Sweet-Cordero EA
    J Clin Invest; 2010 Nov; 120(11):3940-52. PubMed ID: 20972333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
    Rabi T; Catapano CV
    Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression.
    Kamohara H; Ogawa M; Ishiko T; Sakamoto K; Baba H
    Int J Oncol; 2007 Apr; 30(4):977-83. PubMed ID: 17332938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Pleiotropic role, functions and targeted therapies of LIF/LIFR axis in cancer: Old spectacles with new insights.
    Halder S; Parte S; Kshirsagar P; Muniyan S; Nair HB; Batra SK; Seshacharyulu P
    Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188737. PubMed ID: 35680099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma.
    Di Giorgio C; Lupia A; Marchianò S; Bordoni M; Bellini R; Massa C; Urbani G; Roselli R; Moraca F; Sepe V; Catalanotti B; Morretta E; Monti MC; Biagioli M; Distrutti E; Zampella A; Fiorucci S
    Cells; 2022 Nov; 11(21):. PubMed ID: 36359879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
    Viswanadhapalli S; Luo Y; Sareddy GR; Santhamma B; Zhou M; Li M; Ma S; Sonavane R; Pratap UP; Altwegg KA; Li X; Chang A; Chávez-Riveros A; Dileep KV; Zhang KYJ; Pan X; Murali R; Bajda M; Raj GV; Brenner AJ; Manthati V; Rao MK; Tekmal RR; Nair HB; Nickisch KJ; Vadlamudi RK
    Mol Cancer Ther; 2019 Aug; 18(8):1341-1354. PubMed ID: 31142661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1α and STAT3 in KRAS mutant human colon cancer cells.
    Mi C; Cao X; Ma K; Wei M; Xu W; Lin Y; Zhang J; Wang TY
    Chem Biol Interact; 2022 Jan; 351():109729. PubMed ID: 34717917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
    Pei Y; Chen L; Huang Y; Wang J; Feng J; Xu M; Chen Y; Song Q; Jiang G; Gu X; Zhang Q; Gao X; Chen J
    Small; 2019 Jun; 15(24):e1900631. PubMed ID: 31033217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.
    Diersch S; Wirth M; Schneeweis C; Jörs S; Geisler F; Siveke JT; Rad R; Schmid RM; Saur D; Rustgi AK; Reichert M; Schneider G
    Oncogene; 2016 Jul; 35(29):3880-6. PubMed ID: 26592448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.
    Kent OA; Sandí MJ; Burston HE; Brown KR; Rottapel R
    Oncotarget; 2017 Jan; 8(3):4484-4500. PubMed ID: 27835861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells.
    Zhao C; Yang L; Zhou F; Yu Y; Du X; Xiang Y; Li C; Huang X; Xie C; Liu Z; Lin J; Wang L; Liang G; Cui R
    Oncogene; 2020 May; 39(20):3997-4013. PubMed ID: 32242147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.